Advertisement

Drugs and Hair Loss

Published:September 20, 2012DOI:https://doi.org/10.1016/j.det.2012.08.002

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Dermatologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Harrison S.
        • Sinclair R.
        Telogen effluvium.
        Clin Exp Dermatol. 2002; 27: 389-395
        • Kligman A.M.
        The human hair cycle.
        J Invest Dermatol. 1959; 33: 307-316
        • Whiting D.A.
        Chronic telogen effluvium.
        Dermatol Clin. 1996; 14: 723-731
        • Paus R.
        • Cotsarelis G.
        The biology of hair follicles.
        N Engl J Med. 1999; 341: 491-497
        • Harrison S.
        • Bergfeld W.
        Diffuse hair loss: its triggers and management.
        Cleve Clin J Med. 2009; 76: 361-367
        • Gordon K.A.
        • Tosti A.
        Alopecia: evaluation and treatment.
        Clin Cosmet Investig Dermatol. 2011; 4: 101-106
        • Blume-Peytavi U.
        • Blumeyer A.
        • Tosti A.
        • et al.
        S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents.
        Br J Dermatol. 2011; 164: 5-15
        • Pillans P.I.
        • Woods D.J.
        Drug-associated alopecia.
        Int J Dermatol. 1995; 34: 149-158
        • Mercke Y.
        • Sheng H.
        • Khan T.
        • et al.
        Hair loss in psychopharmacology.
        Ann Clin Psychiatry. 2000; 12: 35-42
        • Yun S.J.
        • Kim S.J.
        Hair loss pattern due to chemotherapy-induced anagen effluvium: a cross-sectional observation.
        Dermatology. 2007; 215: 36-40
        • Trueb R.M.
        Chemotherapy-induced alopecia.
        Semin Cutan Med Surg. 2009; 28: 11-14
        • Trueb R.M.
        Chemotherapy-induced anagen effluvium: diffuse or patterned?.
        Dermatology. 2007; 215: 1-2
        • Tosti A.
        • Piraccini B.M.
        • Vincenzi C.
        • et al.
        Permanent alopecia after busulfan chemotherapy.
        Br J Dermatol. 2005; 152: 1056-1058
        • Koppel R.A.
        • Boh E.E.
        Cutaneous reactions to chemotherapeutic agents.
        Am J Med Sci. 2001; 321: 327-335
        • Espinosa E.
        • Zamora P.
        • Feliu J.
        • et al.
        Classification of anticancer drugs–a new system based on therapeutic targets.
        Cancer Treat Rev. 2003; 29: 515-523
        • Selleri S.
        • Arnaboldi F.
        • Vizzotto L.
        • et al.
        Epithelium–mesenchyme compartment interaction and oncosis on chemotherapy-induced hair damage.
        Lab Invest. 2004; 84: 1404-1417
        • Duvic M.
        • Lemak N.A.
        • Valero V.
        • et al.
        A randomized trial of minoxidil in chemotherapy-induced alopecia.
        J Am Acad Dermatol. 1996; 35: 74-78
        • Tosti A.
        • Pazzaglia M.
        Drug reactions affecting hair: diagnosis.
        Dermatol Clin. 2007; 25: 223-231
        • Grevelman E.G.
        • Breed W.P.
        Prevention of chemotherapy-induced hair loss by scalp cooling.
        Ann Oncol. 2005; 16: 352-358
        • Tosti A.
        • Piraccini B.M.
        • Sisti A.
        • et al.
        Hair loss in women.
        Minerva Ginecol. 2009; 61: 445-452
        • Gilmore S.
        • Sinclair R.
        Chronic telogen effluvium is due to a reduction in the variance of anagen duration.
        Australas J Dermatol. 2010; 51: 163-167
        • Mortimer P.S.
        • Dawber R.P.
        Hair loss and lithium.
        Int J Dermatol. 1984; 23: 603-604
        • Orwin A.
        Hair loss following lithium therapy.
        Br J Dermatol. 1983; 108: 503-504
        • Mccreadie R.G.
        • Morrison D.P.
        The impact of lithium in South-west Scotland. I. Demographic and clinical findings.
        Br J Psychiatry. 1985; 146: 70-74
        • Dawber R.
        • Mortimer P.
        Hair loss during lithium treatment.
        Br J Dermatol. 1982; 107: 124-125
        • Jeavons P.M.
        • Clark J.E.
        Sodium valproate in treatment of epilepsy.
        Br Med J. 1974; 2: 584-586
        • Despland P.A.
        Praxis (Bern 1994). 1994; 83 ([in French]): 1132-1139
        • Henriksen O.
        • Johannessen S.I.
        Clinical and pharmacokinetic observations on sodium valproate—a 5-year follow-up study in 100 children with epilepsy.
        Acta Neurol Scand. 1982; 65: 504-523
        • Egger J.
        • Brett E.M.
        Effects of sodium valproate in 100 children with special reference to weight.
        Br Med J (Clin Res Ed). 1981; 283: 577-581
        • Ogilvie A.D.
        Hair loss during fluoxetine treatment.
        Lancet. 1993; 342: 1423
        • Rais T.
        • Singh T.
        • Rais A.
        Hair loss associated with long-term sertraline treatment in teenager.
        Psychiatry (Edgmont). 2005; 2: 52
        • Warnock J.K.
        Psychotropic medication and drug-related alopecia.
        Psychosomatics. 1991; 32: 149-152
        • Wang Y.Y.
        • Po H.L.
        Enoxaparin-induced alopecia in patients with cerebral venous thrombosis.
        J Clin Pharm Ther. 2006; 31: 513-517
        • Barnes C.
        • Deidun D.
        • Hynes K.
        • et al.
        Alopecia and dalteparin: a previously unreported association.
        Blood. 2000; 96: 1618-1619
        • Apsner R.
        • Horl W.H.
        • Sunder-Plassmann G.
        Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulation.
        Blood. 2001; 97: 2914-2915
        • Sarris E.
        • Tsele E.
        • Bagiatoudi G.
        • et al.
        Diffuse alopecia in a hemodialysis patient caused by a low molecular- weight heparin, tinzaparin.
        Am J Kidney Dis. 2003; 41: E15
        • Nagao T.
        • Ibayashi S.
        • Fujii K.
        • et al.
        Treatment of warfarin-induced hair loss with ubidecarenone.
        Lancet. 1995; 346: 1104-1105
        • Umlas J.
        • Harken D.E.
        Warfarin-induced alopecia.
        Cutis. 1988; 42: 63-64
        • Graeber C.W.
        • Lapkin R.A.
        Metoprolol and alopecia.
        Cutis. 1981; 28: 633-634
        • Hilder R.J.
        Propranolol and alopecia.
        Cutis. 1979; 24: 63-64
        • Scribner M.D.
        Propranolol therapy.
        Arch Dermatol. 1977; 113: 1303
        • Martin C.M.
        • Southwick E.G.
        • Maibach H.I.
        Propranolol induced alopecia.
        Am Heart J. 1973; 86: 236-237
        • Leaker B.
        • Whitworth J.A.
        Alopecia associated with captopril treatment.
        Aust N Z J Med. 1984; 14: 866
        • Samuel L.M.
        • Davie M.
        • Starkey I.R.
        Amiodarone and hair loss.
        Postgrad Med J. 1992; 68: 771
        • Mcgovern B.
        • Garan H.
        • Kelly E.
        • et al.
        Adverse reactions during treatment with amiodarone hydrochloride.
        Br Med J (Clin Res Ed). 1983; 287: 175-180
      1. Hair loss and contraceptives.
        Br Med J. 1973; 2: 499-500
        • Se W.
        Comprehensive dermatological drug therapy. Saunders Elsevier, 2007 (p. 431)
        • Seckin D.
        • Yildiz A.
        Repigmentation and curling of hair after acitretin therapy.
        Australas J Dermatol. 2009; 50: 214-216
        • Gupta K.B.
        • Kumar V.
        • Vishvkarma S.
        • et al.
        Isoniazid-induced alopecia.
        Lung India. 2011; 28: 60-61
        • Fitzgerald J.M.
        • Turner M.T.
        • Dean S.
        • et al.
        Alopecia side effect of antituberculosis drugs.
        Lancet. 1996; 347: 472
        • Harry T.C.
        • Matthews M.
        • Salvary I.
        Indinavir use: associated reversible hair loss and mood disturbance.
        Int J STD AIDS. 2000; 11: 474-476
        • Ginarte M.
        • Losada E.
        • Prieto A.
        • et al.
        Generalized hair loss induced by indinavir plus ritonavir therapy.
        AIDS. 2002; 16: 1695-1696
        • Mirena
        Product information leaflet.
        Bayer HealthCare Pharmaceuticals, 2009
        • Garcovich S.
        • Manco S.
        • Zampetti A.
        • et al.
        Onset of lichen planopilaris during treatment with etanercept.
        Br J Dermatol. 2008; 158: 1161-1163
        • Abbasi N.R.
        • Orlow S.J.
        Lichen planopilaris noted during etanercept therapy in a child with severe psoriasis.
        Pediatr Dermatol. 2009; 26: 118
        • Handa S.
        • Sahoo B.
        Childhood lichen planopilaris: a study of 87 cases.
        Int J Dermatol. 2001; 40: 461
        • Fernandez-Torres R.
        • Paradela S.
        • Valbuna L.
        • et al.
        Infliximab-induced lichen planopilaris.
        Ann Pharmacol. 2010; 44: 1501-1503
        • Rosman H.S.
        • Anadkat M.J.
        Tufted hair follicultis in a woman treated with trastuzumab.
        Target Oncol. 2010; 5: 295-296
        • Myskowski P.L.
        • Halpern A.C.
        Skin reactions to the new biologic anticancer drugs.
        Curr Opin Support Palliat Care. 2009; 3: 294-299
        • Graves J.E.
        • Jones B.F.
        • Lind A.C.
        • et al.
        Nonscarring alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
        J Am Acad Dermatol. 2006; 55: 349-353
        • Donovan J.C.
        • Ghazarian D.M.
        • Shaw J.C.
        Scarring Alopecia Associated with use of the epidermal growth factor receptor inhibitor gefitinib.
        Arch Dermatol. 2008; 144: 1524-1525
        • Hepper D.M.
        • Wu P.
        • Anadkat M.J.
        Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
        J Acad Dermatol. 2011; 64: 996-998
        • Hoekzema R.
        • Drillenburg P.
        Folliculitis decalvans associated with erlotinib.
        Clin Exp Dermatol. 2010; 35: 916-918
        • Ena P.
        • Fadda G.M.
        • Ena L.
        • et al.
        Tufted hair folliculitis in a woman treated with lapatinib for breast cancer.
        Clin Exp Dermatol. 2008; 33: 776-794